Central mechanisms controlling appetite and food intake in a cancer setting: an update.

作者: Autumn L Fletcher , Daniel L Marks

DOI: 10.1097/SPC.0B013E3282F14C4E

关键词: Food intakeCancerCachexiaWastingMedicineMelanocortinBioinformaticsDiseaseAppetiteChemotherapy Drugs

摘要: PURPOSE OF REVIEW Cachexia, also known as disease-associated wasting, is an important factor in the mortality of many patients with diseases such cancer, well renal and congestive heart failure. Yet syndrome not yet defined, making diagnosis difficult often subjective on part physician. Nor are central mechanisms cachexia fully elucidated. Recent studies have begun to address these gaps by focusing three areas: role cytokines cachexia, other proteins peptides that might be involved, potential treatments for this devastating syndrome. RECENT FINDINGS Cachexia can caused, absence disease, inflammatory stimuli some chemotherapy drugs, suggesting possible cachexia. Promising include melanocortin antagonism hormones. SUMMARY While more research necessary illuminate causal uncover therapies several its major molecular pathways become elucidated, directions therapeutic approaches.

参考文章(67)
Stephen J. Wigmore, Kenneth C. H. Fearon, Jean P. Maingay, James A. Ross, Down-regulation of the acute-phase response in patients with pancreatic cancer cachexia receiving oral eicosapentaenoic acid is mediated via suppression of interleukin-6. Clinical Science. ,vol. 92, pp. 215- 221 ,(1997) , 10.1042/CS0920215
K A Nelson, D Walsh, F A Sheehan, The cancer anorexia-cachexia syndrome. Journal of Clinical Oncology. ,vol. 12, pp. 213- 225 ,(1994) , 10.1200/JCO.1994.12.1.213
F. POCIOT, J. MØLVIG, L. WOGENSEN, H. WORSAAE, J. NERUP, A Taql polymorphism in the human interleukin-1β (IL-1β) gene correlates with IL-1β secretion in vitro European Journal of Clinical Investigation. ,vol. 22, pp. 396- 402 ,(1992) , 10.1111/J.1365-2362.1992.TB01480.X
Peter W. T. Pisters, David B. Pearlstone, M. H. Toroslan, Protein and amino acid metabolism in cancer cachexia: investigative techniques and therapeutic interventions. Critical Reviews in Clinical Laboratory Sciences. ,vol. 30, pp. 223- 272 ,(1993) , 10.3109/10408369309084669
Giovanni Mantovani, Antonio Macci??, Elena Massa, Clelia Madeddu, Managing cancer-related anorexia/cachexia. Drugs. ,vol. 61, pp. 499- 514 ,(2001) , 10.2165/00003495-200161040-00004
Oya Kayacan, Demet Karnak, Sumru Beder, Emine G??ll??, H??seyin Tutkak, Filiz ??ay ??enler, Deniz K??ksal, Impact of TNF-α and IL-6 levels on development of cachexia in newly diagnosed NSCLC patients American Journal of Clinical Oncology. ,vol. 29, pp. 328- 335 ,(2006) , 10.1097/01.COC.0000221300.72657.E0
Y Wu, K McRoberts, S S Berr, H F Frierson, M Conaway, D Theodorescu, Neuromedin U is regulated by the metastasis suppressor RhoGDI2 and is a novel promoter of tumor formation, lung metastasis and cancer cachexia. Oncogene. ,vol. 26, pp. 765- 773 ,(2007) , 10.1038/SJ.ONC.1209835
Yukari Date, Takuya Shimbara, Shuichi Koda, Koji Toshinai, Takanori Ida, Noboru Murakami, Mikiya Miyazato, Koichi Kokame, Yuta Ishizuka, Yasushi Ishida, Haruaki Kageyama, Seiji Shioda, Kenji Kangawa, Masamitsu Nakazato, Peripheral ghrelin transmits orexigenic signals through the noradrenergic pathway from the hindbrain to the hypothalamus. Cell Metabolism. ,vol. 4, pp. 323- 331 ,(2006) , 10.1016/J.CMET.2006.09.004
Mark D. DeBoer, Daniel L. Marks, Cachexia: lessons from melanocortin antagonism Trends in Endocrinology and Metabolism. ,vol. 17, pp. 199- 204 ,(2006) , 10.1016/J.TEM.2006.05.005
Daniel L. Marks, Andrew A. Butler, Renn Turner, Gregor Brookhart, Roger D. Cone, Differential role of melanocortin receptor subtypes in cachexia. Endocrinology. ,vol. 144, pp. 1513- 1523 ,(2003) , 10.1210/EN.2002-221099